BSX Stock Dividend, Drop, Price Target, and Fair Value – Complete Analysis

Boston Scientific (BSX) has become one of the most talked-about stocks in 2026, but for all the wrong reasons. After crashing from its September 2025 peak of $109.50 to a 52-week low of $42.20, investors are asking tough questions. Does BSX pay a dividend? Why is the stock dropping so sharply? What are analysts saying about the price target? Is it a buy or sell right now? And what’s the fair value? This article breaks down everything you need to know about BSX stock.

Does BSX Stock Pay a Dividend?

No, Boston Scientific (BSX) does not pay a dividend. According to the company’s official investor communications, Boston Scientific has no active cash dividend, no dividend reinvestment plan, and no direct stock purchase plan. Financial data providers consistently report a dividend of $0.00 per share with a 0.00% yield.

Why Doesn’t BSX Pay a Dividend?

Boston Scientific is a growth stock that prioritizes reinvesting profits back into the business. The medical device industry requires heavy investment in research and development, clinical trials, regulatory approvals, manufacturing capacity, and strategic acquisitions. Instead of returning cash to shareholders through dividends, the company focuses on funding innovation and expansion. This is a common strategy among high-growth healthcare companies that are still in their expansion phase.

Buybacks Instead of Dividends

While BSX doesn’t offer dividend income, it has authorized a $5 billion share-repurchase program, which covers up to 6.4% of outstanding shares. Stock buybacks reduce the number of shares outstanding, which can increase earnings per share and potentially boost the stock price over time. This is the company’s primary method of returning value to shareholders. For investors seeking regular income, BSX is not the right choice, but for those focused on capital appreciation, the buyback program offers some indirect benefit.

Why Is BSX Stock Dropping?

Boston Scientific has lost more than half its market value, with the stock down approximately 57% from its peak and about 52% year-to-date. Several factors are driving this decline, and understanding them is crucial for any potential investor.

The WATCHMAN Product-Line Collapse

The primary culprit is the WATCHMAN left atrial appendage closure device, once Boston Scientific’s flagship product. Management warned of flat sequential U.S. WATCHMAN sales in both the second and third quarters of 2026, citing physician workflow constraints, clinical trial headwinds, and reimbursement friction. That single product-line stumble erased more than half the company’s market value. At least seven analyst firms slashed price targets this month alone following this announcement. The WATCHMAN device was previously a high-growth driver for the company, and its sudden slowdown has shocked investors who had priced in continued strong performance.

Analyst Downgrades and Price Target Cuts

A wave of analyst downgrades followed the WATCHMAN news. Several major firms cut their price targets significantly:

UBS lowered its target from $95 to $74 while maintaining a Buy rating. Oppenheimer reduced its target from $90 to $85 with an Outperform rating. Mizuho cut from $90 to $70 with an Outperform rating. Needham made a substantial cut from $77 to $57 while keeping a Buy rating. Stifel Nicolaus lowered from $75 to $65 with a Buy rating. BTIG reduced from $80 to $65 with a Buy rating. Truist cut from $85 to $64 with a Buy rating. Bank of America made a dramatic cut from $105 to $68 while maintaining a Buy rating.

Analysts have cut their targets citing slower growth expectations for the WATCHMAN franchise, but notably, almost all have maintained Buy or Outperform ratings. No one has turned bearish on the stock, which suggests that the fundamental story remains intact despite the near-term challenges.

FDA Device Alert

Adding to the negative sentiment, the FDA issued an early alert on Boston Scientific’s ENROUTE Transcarotid NPS device over catheter tip separation risks, with one serious injury reported. BSX initiated a product lot recall. While this issue appears smaller in scale compared to the WATCHMAN problems, it adds to the regulatory headwinds and negative headlines surrounding the company. Investors are concerned that more regulatory issues could emerge as the company undergoes its restructuring.

Restructuring Costs and Uncertainty

On July 27, 2026, Boston Scientific announced a global restructuring plan with estimated charges of $700 million to $800 million. The plan includes $300 million to $350 million in production transfer costs, $275 million to $300 million in employee termination benefits, and $125 million to $150 million in other functional transformation costs. The plan is expected to generate $500 million in annual pre-tax expense savings but won’t be substantially complete until 2029. While the savings are positive long-term, the near-term uncertainty has weighed on the stock. Job cuts and restructuring always create uncertainty, and investors typically punish stocks during such transitions.

BSX Stock Price Target: What Do Analysts Expect?

Despite the steep drop, Wall Street remains surprisingly optimistic about Boston Scientific’s future.

Consensus Price Target

According to 31 analysts polled by S&P Global, the consensus rating is Strong Buy, with an average price target of approximately $72.31. This represents roughly 57% upside from current levels. The median price target stands at $70.00, with the highest target at $106.00 and the lowest at $55.00. Current trading levels are around $46.00, which means even the lowest analyst target suggests some upside potential.

Analyst Ratings Breakdown

The breakdown of analyst ratings is remarkably bullish. Twenty analysts have issued a Strong Buy rating. Seven analysts have issued a Buy rating. Four analysts have issued a Hold rating. Notably, zero analysts have issued a Sell or Strong Sell rating. This unanimous bullishness is rare for a stock that has dropped so sharply, and it suggests that analysts believe the market has overreacted to the WATCHMAN news.

Key Analyst Comments

UBS maintained a Buy rating at $74, noting that the stock is trading near five-year lows with no structural change to business fundamentals. They believe the stock is pricing in unrealistic multi-year sales declines. The PEG ratio of approximately 0.24 to 0.26 suggests the stock is attractively valued relative to its growth prospects. Canaccord Genuity reiterated a Buy rating and $70 target, stating the stock appears undervalued following the restructuring announcement. Several other analysts have echoed these sentiments, pointing to the company’s strong pipeline of new products beyond WATCHMAN.

BSX Stock Fair Value

InvestingPro Fair Value Estimate

According to InvestingPro data, the Fair Value estimate for BSX is approximately $63.70, implying roughly 38% upside from the current price. This estimate is based on a combination of valuation models, including discounted cash flow analysis, comparable company analysis, and forward earnings projections.

What Does Fair Value Mean Here?

Fair value is an estimate of what the stock should be worth based on fundamentals like earnings growth, revenue projections, and industry comparisons. At $63.70, the stock is considered undervalued at current levels. However, fair value estimates are only as good as the assumptions behind them. If the WATCHMAN issues persist longer than expected, the fair value could be revised downward. Conversely, if the company resolves these issues quickly, the stock could trade above fair value.

PEG Ratio Suggests Undervaluation

The PEG ratio is a key valuation metric that compares the P/E ratio to the earnings growth rate. A PEG below 1.0 typically suggests undervaluation. BSX’s PEG ratio is approximately 0.24 to 0.26, which implies the market is pricing in much lower growth than analysts expect. This suggests that the current stock price already reflects significant pessimism about the company’s future.

Earnings and Revenue Growth

Boston Scientific reported second quarter 2026 revenue of $5.44 billion, beating analyst estimates of $5.36 billion, with sales up 7.5% year-on-year. Adjusted EPS was $0.86, beating estimates of $0.83 by nearly 4%. Management’s full-year EPS guidance was lowered to $3.30 at the midpoint, a decrease of about 2.2%, and third quarter revenue guidance of $5.27 billion missed expectations. Despite the guidance miss, the stock traded up nearly 3% after the earnings report, suggesting investors were relieved the quarter wasn’t worse.

BSX Stock: Buy or Sell?

This is the million-dollar question for investors. Here’s a balanced breakdown of the bull and bear cases to help you make an informed decision.

The Bull Case – Reasons to Buy

• First, there is massive upside potential. The average price target of $72.31 implies approximately 57% upside. Even the lowest target of $55 suggests nearly 20% upside. The stock is trading well below even the most conservative analyst estimates.

• Second, valuation metrics suggest undervaluation. The PEG ratio of approximately 0.24 to 0.26 suggests the market is pricing in worst-case scenarios. InvestingPro’s Fair Value estimate of $63.70 implies 38% upside. The stock has rarely been this cheap relative to its growth rate.

• Third, there is strong analyst conviction. There are 27 Buy or Strong Buy ratings and zero Sells. Analysts are unanimously positive despite the selloff. This level of consensus is unusual and suggests that analysts see a clear path to recovery.

• Fourth, the restructuring is expected to generate $500 million in annual cost savings by 2029. This will boost cash flow and profitability significantly. The company is taking decisive action to cut costs and streamline operations.

• Fifth, the technical picture is showing signs of a bounce. The stock has bounced approximately 7% this week, and the daily RSI has recovered to 55, suggesting short-term momentum is improving. The stock may have found a bottom near the $42 level.

• Sixth, there has been insider buying. Directors purchased shares in May 2026 at prices around $55 to $56, indicating confidence at levels higher than the current price. Insiders rarely buy stock unless they believe it’s undervalued.

The Bear Case – Reasons to Sell or Wait

• First, WATCHMAN uncertainty remains the biggest risk. The flagship product’s sales are flat, and the recovery timeline is unclear. The Q2 earnings call will be critical to understanding whether this is a temporary speed bump or a longer-term issue. If the problems persist, the stock could fall further.

• Second, restructuring costs are significant. The $700 million to $800 million in charges and job cuts through 2029 create near-term execution risk. The company is undergoing major changes, and execution missteps could worsen the situation.

• Third, the guidance miss is concerning. Third quarter revenue guidance of $5.27 billion missed expectations, and full-year EPS guidance was lowered. This suggests that management itself is cautious about the near-term outlook.

• Fourth, the FDA device alert adds regulatory risk. The ENROUTE device recall creates additional headline noise and could lead to further regulatory scrutiny. This is a reminder that medical device companies always face regulatory risk.

• Fifth, the technical damage is severe. Weekly indicators show a strong sell signal with RSI at 28.8, which is deeply oversold. The MACD is deeply negative, and the ADX is at 57, indicating a powerful downtrend. The stock needs to break above $47.20 for the first constructive technical signal.

The Verdict

If you believe the WATCHMAN issues are temporary and the company’s long-term growth story remains intact, the stock looks attractively valued at current levels. The combination of strong analyst support, reasonable valuation metrics, and the potential for a recovery makes it an intriguing opportunity for long-term investors.

However, today’s Q2 earnings call is everything. It will determine whether this is a buying opportunity or a value trap. The market is waiting for clarity on the WATCHMAN situation, and the management’s comments on the call will be closely scrutinized. Aggressive investors may choose to buy ahead of the call, while more cautious investors may wait for confirmation that the worst is over.

Key Information Summary

Boston Scientific does not pay any dividend, with a dividend of $0.00 per share and 0.00% yield. The stock has dropped approximately 57% from its peak of $109.50 to around $46.00. The primary reason is collapsing sales of the WATCHMAN device, along with analyst downgrades, an FDA device alert, and a major restructuring plan.

The consensus price target is $72.31 from 31 analysts, implying 57% upside. The median target is $70.00, with targets ranging from $55 to $106. The InvestingPro fair value estimate is $63.70, implying 38% upside. The PEG ratio of 0.24 to 0.26 also suggests undervaluation.

The consensus rating is Strong Buy, with 27 analysts rating it Buy or Strong Buy and zero analysts rating it Sell. The bull case rests on massive upside potential, attractive valuation, strong analyst conviction, restructuring savings, technical bounce signals, and insider buying. The bear case highlights WATCHMAN uncertainty, restructuring costs, a guidance miss, FDA regulatory risk, and severe technical damage.

Bottom Line

Boston Scientific is at a critical juncture. The stock has been cut in half, investor confidence is shaken, and the WATCHMAN device, once the company’s crown jewel, is now its biggest headache. Yet Wall Street remains overwhelmingly bullish, with average price targets pointing to massive upside.

The Q2 earnings call on July 29, 2026, will be pivotal. If management can articulate a credible path to WATCHMAN recovery and reaffirm long-term growth targets, the stock could rebound sharply. If not, more downside is possible.

For long-term investors with a high risk tolerance, BSX could be a compelling value play. For those seeking safety or dividend income, this is not the right stock. The company doesn’t pay dividends, and the near-term outlook remains uncertain. As always, do your own research and consider your risk appetite before making any investment decision.

Disclaimer: The information provided in this article is for educational and informational purposes only. It does not constitute financial, investment, or trading advice. Stock market investing involves risks, and you should always consult your financial advisor before making any investment decision. The author and publisher are not liable for any financial losses or gains. Past performance is not a guarantee of future results. Please conduct independent research and assess your risk tolerance before investing.